{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:15:33Z","timestamp":1770509733885,"version":"3.49.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/ftd.0b013e318220bb65","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T06:52:15Z","timestamp":1307429535000},"page":"398-401","source":"Crossref","is-referenced-by-count":4,"title":["Performance Characteristics of the ARK Diagnostics Gabapentin Immunoassay"],"prefix":"10.1097","volume":"33","author":[{"given":"JoEtta M","family":"Juenke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavina A","family":"Wienhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent L","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendolyn A","family":"McMillin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamisha L","family":"Johnson-Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210129","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of newer anti-epilepsy Medications.","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals"},{"key":"R2-5-20210129","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/157488710792007310","article-title":"Gabapentin for the treatment of cancer-related pain syndromes.","volume":"5","author":"Bar Ad","year":"2010","journal-title":"Rev Recent Clin Trials"},{"key":"R3-5-20210129","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/1658-354X.71409","article-title":"Study of the effect of oral gabapentin used as preemptive analgesia to attenuate post-operative pain in patients undergoing abdominal surgery under general anesthesia.","volume":"4","author":"Parikh","year":"2010","journal-title":"Saudi J Anaesth"},{"key":"R5-5-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1213\/ANE.0b013e3181fdf5ee","article-title":"Gabapentin improves postceserean delivery pain management: a randomized, placebo-controlled trial.","volume":"112","author":"Moore","year":"2011","journal-title":"Anesth Analg"},{"key":"R6-5-20210129","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","article-title":"Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.","volume":"280","author":"Backonja","year":"1998","journal-title":"JAMA"},{"key":"R7-5-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1526-4610.2001.111006119.x","article-title":"Efficacy of gabapentin in migraine prophylaxis.","volume":"41","author":"Mathew","year":"2001","journal-title":"Headache"},{"key":"R8-5-20210129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e3182087d48","article-title":"A 52-week study of gabapentin enacarbil in restless legs syndrome.","volume":"34","author":"Ellenbogen","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"R9-5-20210129","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/NDT.S13407","article-title":"Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study.","volume":"6","author":"Gabriel","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R10-5-20210129","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00004714-200008000-00011","article-title":"Placebo-controlled study of gabapentin treatment of panic disorder.","volume":"20","author":"Pande","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R11-5-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","article-title":"Treatment of social phobia with gabapentin: a placebo-controlled study.","volume":"19","author":"Pande","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R12-5-20210129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":"Inter- and Intra-subject variability in gabapentin absorption and absolute bioavailability.","volume":"40","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"key":"R13-5-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R14-5-20210129","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00007691-200308000-00007","article-title":"Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study.","volume":"25","author":"Lindberger","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R15-5-20210129","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1373\/49.7.1198","article-title":"Procedure for the monitoring of gabapentin with 2,4,6-trinitrobenzene sulfonic acid derivatization followed by HPLC with ultraviolet detection.","volume":"49","author":"Juenke","year":"2003","journal-title":"Clin Chem"},{"key":"R16-5-20210129","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00216-010-4048-2","article-title":"Dried plasma spots as an alternative sample collection technique for the quantitative LC-MS\/MS determination of gabapentin.","volume":"398","author":"Kolocouri","year":"2010","journal-title":"Anal Bioanal Chem"},{"key":"R17-5-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jat\/23.1.1","article-title":"Analysis of gabapentin in serum and plasma by solid phase extraction and gas chromatography-mass spectrometry for therapeutic drug monitoring.","volume":"23","author":"Kushnir","year":"1999","journal-title":"J Anal Toxicol"},{"key":"R18-5-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/FTD.0b013e31820b1fce","article-title":"Simultaneous Quantification of levetiracetam and gabapentin in plasma by ultrahigh-pressure liquid chromatography with tandem mass spectrometric detection.","volume":"33","author":"Juenke","year":"2011","journal-title":"Ther Drug Monitor"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318220bb65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T18:25:43Z","timestamp":1637778343000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201108000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318220bb65","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}